A New Jersey jury ruled that Novartis , provided adequate warnings about the risk of its bone-strengthening medicines, rejecting a lawsuit by a woman who claimed the drugs destroyed her jaw.
Jane Bessemer, 73, sued Novartis after developing jawbone damage while taking Aredia and Zometa to slow bone loss as she battled breast cancer. Jurors in state court in New Brunswick, New Jersey, ruled that Novartis provided adequate warning to Bessemer’s physician of jaw problems from Aredia and Zometa.
Both drugs are still on the market.
Last year, a Montana jury ordered Novartis to pay $3.2 million in damages to a woman who blamed the drug for damaging her jaw.
Read more here.
